Introduction
immunosuppressive properties of FK506 and its superior potency over CsA [9] . However, these animal studies also revealed that FK506 had major side effects, including neurotoxicity and nephrotoxicity, much like CsA [9, 10] . At the time, this toxicity dampened the enthusiasm about the prospect of developing FK506 as a therapeutic immunosuppressant. It was feared that despite its increased immunosuppressive activity, FK506 would not be any better than CsA, which had become the established mainstay for transplant rejection prophylaxis after its introduction in the early 80s. This notion was boldly challenged by Starzl and collaborators who initiated trials with FK506 as rescue therapy in human liver transplant patients who did not fare well with CsA treatment. It was quickly apparent that in many of these patients, FK506 proved quite beneficial and had a lifesaving effect [11] . These encouraging findings were further substantiated upon extended use of the drug in a larger group of patients [12, 13] , providing the impetus for controled, multi-center clinical trials of FK506 as a primary therapy in liver and kidney transplantation. It was demonstrated that indeed, FK506-based therapy offers a number of potential advantages over conventional CsA-based treatment, such as a corticosteroid-sparing action and a significant reduction in incidence of both acute and corticosteroid-FK506 (Tacrolimus, Prograf TM ) is a 23-member ring macrolide lactone ( Fig. 1 ) that was discovered in 1984 by scientists at Fujisawa Pharmaceutical Co (Japan) in the fermentation broth of the filamentous bacterium, Streptomyces tsukubaensis [1] . It belongs, together with cyclosporin A (CsA) [2] and rapamycin [3] , to a unique class of immunosuppressive natural products whose major pharmacologic attributes stem from an ability to perturb certain intracellular signal transduction processes of T lymphocyte activation. Early studies demonstrated the extraordinary potent immunosuppressive properties of FK506 in vitro [4] . At subnanomolar concentrations, it was shown to inhibit the proliferation of murine or human T cells stimulated by specific antigens, antibodies to the T cell receptor (TCR)/CD3 complex or mitogenic lectins as well as the generation of cytolytic T cells (CTL) in mixed lymphocyte reactions [5] [6] [7] . In these initial experiments, it became clear that FK506 exerts its activity in a manner strikingly similar to CsA, by disrupting calcium signaling events that lead to lymphokine production, but with 50-100-fold higher potency [6] [7] [8] . Numerous studies in animal models of transplantation confirmed the resistant rejection episodes [14, 15] . FK506 was approved by the FDA for the prophylaxis of liver transplant rejection in 1994 and kidney transplant rejection in 1997. The drug is being further evaluated in pilot studies for the treatment of cardiac, pulmonary, intestinal and pancreatic transplant rejection [14] , of graft-versus-host disease [16] and of various allergic or autoimmune conditions (The European FK506 Multicentre Psoriasis Study Group) [17, 18, 19] . FK506 may also prove useful as an adjunct therapeutic agent for xenotransplantation [20] .
was shown to exhibit, like the latter, a peptidyl-prolyl cistrans isomerase (PPIase) enzymatic activity, defined as the catalysis of the slow cis to trans isomerization by Xaa-proline peptide bond in short synthetic peptides [22] . Subsequently, it was found that FKBP12 is not unique to T cells and belongs to a large family of homologous proteins with wide phylogenetic and tissue distribution [29] . Several mammalian FKBPs of different sizes, which all bind FK506, but with different affinities, and possess PPIase activity, have now been characterized ( Table 1) .
The clinical exploitation of the exceptional immunosuppressive properties of FK506 has generated an enormous interest in elucidating its mechanism of action. The major breakthrough that led to a better understanding of this mechanism was the discovery in 1991 by Schreiber and collaborators [21] that upon formation of a complex with the intracellular protein, FK506-binding protein 12 (FKBP12) [22] , the drug selectively inhibits the enzymatic activity of the calcium/calmodulin-dependent protein phosphatase, calcineurin (CaN)) [23] . Astoundingly, it was found that CsA also targets CaN [21] , following interaction of the drug with cyclophilin (Cyp), a CsA-binding protein structurally unrelated FKBP12 [24] . Therefore, two totally different chemical entities bound to two totally different intracellular receptors, or immunophilins [25] were shown to acquire the ability to inhibit a common biochemical target. While explaining the similarity in the immunosuppressive activity profiles of FK506 and CsA, this unveiled an unprecedented pharmacological mechanism whereby the compounds behaved as "codrugs" of endogenous cellular proteins. These studies also put CaN in the limelight and revealed its vital role during T cell activation, as a key signal transducer of lymphokine gene regulation [26] . However, the ubiquitous organ distribution of this enzyme [23] appears to represent the major flaw in the mode of biochemical action of FK506 and CsA, as indirect evidence was obtained that CaN inhibition may mediate the toxic side-effects of both drugs [27, 28] .
Although the exact physiological role of these various FKBPs is still obscure, it seems likely that they function as molecular chaperones facilitating the folding and intracellular transport of proteins and maintaining the stability of multiprotein complexes. This is the case for FKBP51 and FKBP52, which are part of a multimolecular chaperone complex comprising hsp70, hsp90 and other proteins, that modulate the assembly of steroid receptors [30] [31] [32] [33] . On the other hand, FKBP12 has been shown to physiologically interact with the two major intracellular calcium channels, the ryanodine (Ry) receptor [34] and the IP3 receptor [35] . In both instances, FKBP12 is tightly associated with the receptor, where it stabilizes the closed conformation of the channel, and these receptors can be activated to release Ca 2+ upon dissociation of FKBP12 by addition of micromolar concentrations of FK506 [35, 36] . The recent generation of FKBP12-deficient mice [37] confirmed the role of this immunophilin in modulating the calcium release activity of Ry receptors and further established that FKBP12 is essential for the regulation of not only the skeletal receptor [34] , but also of the cardiac one. In fact, such mice developed lethal cardiomyopathy possibly related to cardiac Ry receptor dysfunction [37] . In contrast, the lack of FKBP12 in these mice did not cause any detectable alteration in TGF-β-mediated signaling, even though FKBP12 normally binds to the type I receptor for TGF-β [38, 39] .
Since the natural function of FKBPs is unlikely to serve as receptor for FK506, one may wonder about the existence of endogenous ligand(s) for these proteins. A novel protein, FAP48, which interacts with both FKBP52 and FKBP12, and may represent such a natural ligand, has been isolated [31] . However, the function of this protein is not known, and a potential FK506-mimetic motif within its structure has not been identified. It has also been proposed that the conserved proline-rich motif in the cytoplasmic domain of cytokine receptors might be a ligand for FKBP12, but the functional relevance, if any, of such a putative interaction is unknown [40] . Recently, it was shown that the peptide sequence within the IP3 receptor that binds to FKBP12 is a leucyl-proline dipeptide [35] . This sequence may represent a universal ligand selective Despite these progresses, many questions concerning the precise mechanisms of FK506 immunosuppression and toxicity are still unanswered. Research addressing these questions has remained very active over the past few years. It is the purpose of this review to summarize the most recent advances illuminating further the mode of action of this clinically important drug. [22, 41] , associated with the receptors for ryanodine [34] , IP3 [35] and TGF-β [38] yes FKBP12.6 Associated with the cardiac ryanodine-receptor [42] yes FKBP13 ER-located, abundant in mast cells [43] , associated with erythrocyte membranes [44] no
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Greater affinity for rapamycin than for FK506 [45] , nuclear, bound to caseine kinase II and nucleolin [46] no FKBP51 (54) Associated with FKBP52 in hsp90-progesterone-receptor complexes [31, 47] weak FKBP52 (59) Associated with hsp90 in steroid receptors, [48] nuclear and cytoskeleton-associated [49, 50] no FKBP65 ER-located, contains four FKBP13-like domains, associated with Raf-1 and tropoelastin [51] [52] [53] unknown for FKBP12, inasmuch as the chemical structure of FK506 resembles a leucyl-proline dipeptide [35] . It has therefore been postulated that by interacting with such a motif on other proteins, FKBP12 may serve as an anchor linking CaN to appropriate cellular substrates of its phosphatase activity [35] . This is an interesting hypothesis that certainly deserves further investigation, and the FKBP12 knock-out mice [37] should prove invaluable for that purpose. In the case of FKBP12.6 [42] , another potential physiologically relevant ligand was recently described, namely cyclic-ADP-ribose (cADPR) [54] , a second messenger for Ca 2+ mobilization via the Ry receptor. This small molecule was shown to bind with high affinity (Kd = 35 nM) to FKBP12.6 and to dissociate the immunophilin from the Ry receptor in islet cell microsomes, leading to the release of Ca 2+ [54] . At present, it is not known whether cADPR also interacts with FKBP12.
FKBP12 with high affinity, can block its PPIase activity [27] . Such results supported the "gain-of-function" model stipulating that FK506 acts, not by ablating the natural function of FKBP12, but instead by imparting a new function to the protein [55] . This model is indeed consistent with the observation that FK506 fully inhibits T cell activation at concentrations where it occupies only a minor fraction (3-5%) of the intracellular pools of FKBPs [56] . Therefore, upon ligation of the drug, a small number of FKBP molecules acquire a new role as regulators of another activity, critically involved in the transduction of IL-2-inducing intracellular signals.
The first evidence that CaN is the molecular target for the FKBP12/FK506 complex was obtained using an immobilized FKBP12 matrix. The two subunits of CaN and calmodulin [23] were found to be retained on this affinity gel in the presence, but not in the absence of FK506 [21] . Similarly, immobilized Cyp in presence of CsA retained the protein phosphatase [21] . Moreover, both the FK506/FKBP12 and the CsA/Cyp complexes were shown to inhibit the phosphatase activity of CaN, while neither the immunophilins alone, nor the drugs alone were able to modulate this activity [21] , thereby fulfilling the predictions of the gain of function model [55] .
Inhibition of CaN by the FKBP12/FK506 Complex
Since both FKBP12 and Cyp possess PPIase activity, it was originally postulated that inhibition of this activity by FK506 and CsA, respectively, might account for the similar pharmacological profiles of the drugs [22] . However, this hypothesis was rapidly dismissed by the finding that rapamycin potently inhibits the PPIase activity of FKBP12, even though its mode of action is clearly distinct from that of FK506, in that it does not inhibit Ca 2+ -dependent lymphokine gene induction but rather interferes with the proliferative response of T cells to growth-promoting lymphokines [3, 6] . Likewise, non-immunosuppressive analogs of FK506, such as L-685,818 (Fig. 1 ) which binds to
The pharmacological relevance of the inhibition of CaN phosphatase activity towards peptide substrates by the FK506/FKBP12 complex, was examined using structural analogs with different immunosuppressive activity. Most notably, the complexes formed between FKBP12 and rapamycin or L-685,818 proved unable to significantly affect CaN function [21, 27] . Furthermore, the activity of endogenous CaN in Jurkat T cells could be inhibited by FK506 in a dose-dependent manner paralleling the inhibition of IL-2 production [57] . The activation of normal human T cells also correlates with CaN activity and its inhibition by CsA or FK506 [58] . Moreover, CaN activity was shown to be inhibited in lymphocytes from Behcet's disease patients receiving FK506 immunosuppressive therapy [59] .
the surface of CaN interacting with the FKBP12/FK506 complex was found to render T cells resistant to inhibition by FK506 [61] . Altogether, these experiments clearly established that CaN plays a key function during T cell activation and that inhibition of this function represents the molecular mechanism of both FK506 and CsA immunosuppressive action. Molecular genetic studies using a truncated version of the catalytic subunit (A) of CaN with constitutive phosphatase activity further demonstrated the relationship between CaN activity and IL-2 promoter activation in T cells [59, 60] . Morever, overexpression of a catalytic CaN subunit mutated at residues that lie on The complex formed between FKBP12 and FK506 impedes access of CaN to its substrates and thereby, prevents the nuclear translocation or activation of these factors. The nuclear localization of NFAT is reversible and the protein will return to the cytoplasm when CaN is inactivated (e.g. by FK506, or if Ca 2+ levels fall), due to its rephosphorylation by the GSK3 kinase. Note that CaN may also affect the function of the c-jun N-terminal kinase, JNK and of Elk-1, which are components of Ras/PKCdriven signaling mechanisms.
the drug sensitivity of the cells [62] . Furthermore, in cells overexpressing both the catalytic and regulatory subunits of CaN, which exhibit reduced sensitivity to FK506, it was found that overexpression of FKBP12 could restore drug sensitivity [42] . Interestingly, transfection of the related immunophilin FKBP12.6 also allowed such cells to regain sensitivity to the inhibitory effect of FK506 on IL-2 promoter activation [42] . In fact, of the mammalian FKBP family members currently known (Table 1) , FKBP12 and FKBP12.6 are the only ones that are potent CaN inhibitors when complexed with FK506. Although FKBP51 plus FK506 weakly inhibits CaN in vitro, the relevance of such an activity in mediating the immunosuppressive action of the drug in cells has not been demonstrated [47] .
region on the surface of the complex that promotes its binding to the phosphatase [74] .
The FKBP12/FK506 complex has been shown to make contact with both the catalytic (A) and regulatory (B) subunits of CaN [76, 77] , the interaction with CaNA occuring seemingly at the B subunit binding domain [76] . The X-ray structure of the ternary complex formed between the FKBP12/FK506, a bovine CaNA fragment missing the calmodulin-binding region and CaNB, indicated that the immunophilin/drug complex inhibits the dephosphorylation activity of CaN by physically hindering the approach of protein substrates to the active site, rather than by directly blocking this site [78] . Further analysis of the X-ray structure of full-length human CaN and of its ternary complex with FKBP12/FK506 also suggested that in addition to indirect physical hindrance of substrate binding, the inhibitory properties of the immunophilin/drug complex may be due to long-distance dynamic or structural effects imposed on the active site residues of the enzyme [79] . It is particularly remarkable that the FKBP12/FK506 complex does not appear to directly target the catalytic site of CaN. This, together with the dependence on the B subunit for the interaction between FKBP12/FK506 and CaN to take place [76, 77] , may at least partially account for the specificity of FK506 for CaN versus other serine/threonine phosphatases (e.g. PP-1, PP-2A or PP-2C) [80] which have related catalytic sites but different regulatory subunits [81] .
Biophysical Characterization of the FKBP12/FK506 Complex and of its Interaction with CaN
Biophysical studies confirmed that the FK506/FKBP12 complex is a unique macromolecular species displaying features not shown by the protein or the drug alone. FKBP12 has a compact globular architecture, containing a five-stranded antiparallel β-sheet and a short α-helix [63] . FK506 binds in an ovalshaped site between the sheet and the helix, and makes contact with the protein through four intermolecular hydrogen bonds and via hydrophobic interactions [64, 65] , the latter dominating in the stabilization of the drug binding [66] . Such an interaction does not require the PPIase activity of the immunophilin [67] . Interestingly, it is the minor drug conformer pre-existing in solution, where the pipecolinyl amide moiety is twisted to a trans conformation, that preferentially binds to FKBP12 [64, 68] . While the pipecolinyl and pyranose rings, the dicarbonyl region, and one edge of the cyclohexane ring are in contact with FKBP12, the rest of the macrocycle and the other edge of the cyclohexane ring are exposed on the surface of the complex [64, 65] . Among the residues exposed on this surface, the C15, C18 and C21 moieties appear critically involved in the interaction of the complex with CaN [21, [69] [70] [71] . Indeed, a simplified structure incorporating such residues was found to inhibit CaN phosphatase activity when complexed with FKBP12 [72] . On the other hand, mutational analyses of FKBP12 demonstrated that charged amino acids (Arg42 and His87) exposed within two separate loop regions (residues 40-44 and 84-91) on the surface of the protein, and in the close vicinity of the bound drug, are crucial for the interaction with CaN [73] [74] [75] . Therefore, chemical groups from both FK506 and FKBP12 are involved in the interaction of the drug-immunophilin complex with CaN. The combination of these various residues results in the formation of a contiguous, largely hydrophobic
Mechanism of Inhibition of IL-2 Gene Transcription by FK506
The critical functional consequence of the inhibition of CaN activity by FK506 in T cells is the suppression, at the gene transcription level, of the production of multiple lymphokines [8] , including IL-2, which plays a prominent role in driving T cell growth and differentiation. Given the importance of IL-2 for T cell responses, a great deal of research has focused on the analysis of the regulation of IL-2 gene transcription and of its inhibition by FK506.
The IL-2 gene is regulated by an enhancer/promoter complex that spans ~ 300 bp immediately upstream to the coding region, and comprises at least five elements [26] . These DNA elements bind several protein factors acting in a cooperative fashion to initiate transcription. Several of these factors, such as AP-1, Oct-1 and NF-κB, are ubiquitous and play a role in the regulation of many genes by various stimuli. In contrast, the nuclear factor from activated T cells (NFAT), whose expression was originally believed to be lymphoid cell-specific, has somewhat more exclusive functions [26] . Inhibition of the activities of the latter factor and of Oct-1 and NF-κB were shown to be involved in the suppressive effect of FK506 on IL-2 transcription [26, 82] (Fig. 2 ) .
domain that controls Ca 2+ -dependent subcellular location. In mature T and B lymphocytes, NFATc1, NFATc2 and NFATc3 are co-expresssed but form independent DNA binding complexes [89] . At physiologic concentrations, NFATc1 and NFATc2 can out-compete NFATc3 for occupancy of NFAT sites of the IL-2 promoter, suggesting that NFATc1 and NFATc2 have overlapping functions while the activity of the latter may be more unique [89] . Indeed, the CaNstimulated nuclear translocation of NFATc3, but not of NFATc1 and NFATc2, was shown to be opposed by the JNK signal transduction pathway [90] .
Inhibition of NFAT Activity
Early studies demonstrated a pronounced reduction of NFAT binding activity in nuclear extracts from T cells treated with FK506, suggesting that the drug interferes with the synthesis and/or transport of this factor into the nucleus [82] . Subsequently, is was found that transcriptionally active NFAT is actually composed of two subunits, one which is a constitutively expressed phosphoprotein present in the cytoplasm of unactivated T cells and the other, which is newly synthetized and corresponds to AP-1, induced via the Ras/PKC pathway [83] [84] [85] . Upon activation, these two subunits associate as a multimeric complex within the nucleus to form the fully competent NFAT factor capable of binding to the IL-2E site and to enhance IL-2E-dependent transcription. FK506 was shown to block the assembly of functional NFAT transcription factor, by preventing the nuclear translocation of the cytoplasmic component [83] [84] [85] . It has now become clear that this effect of FK506 is mediated by its inhibition of CaN and contributes to the drug's immunosuppressive action [86] (Fig. 2 ).
In agreement with the studies mentioned above [83] [84] [85] , all three NFAT family members present in the cytoplasm of T cells were found to be phosphorylated and to be substrates for CaN. In fact, CaN was shown to bind to NFATc1 and NFATc2 through a direct proteinprotein interaction with a portion of their N-terminal region [98] . Interestingly, although this interaction is of moderate affinity, it appears specific and can be disrupted by small peptides containing the sequence SPRIEIT [99] . The elevation of intracellular Ca 2+ concentration ([Ca 2+] i ) that ensues TCR triggering induces the activation of CaN, enabling it to dephosphorylate NFAT. This unmasks two nuclear localization signals [100] which in turns, leads to the translocation of NFAT proteins, in association with CaN, to the nucleus [100, 101] . In the nucleus, NFAT then assembles with accessory factors, such as AP-1 [102] into a transcriptionally active complex that forms a continuous groove recognizing 15 bp on the IL-2 promoter [103, 104] . Noteworthily, the retention of NFAT within the nucleus requires the continuous activation of CaN through sustained [Ca 2+] i elevation [105, 106] . When [Ca 2+] i levels fall, NFAT is exported rapidly back to the cytoplasm [105, 107] . This rapid nuclear export of NFAT is due to the presence of a nuclear export signal sequence within NFAT [108] and reflects a dynamic equilibrium between CaN-mediated dephosphorylation and kinase-mediated rephosphorylation events [109, 110] . The glycogen synthase kinase, GSK3, in conjunction with PKA, appear to be involved in NFAT phosphorylation, The cytoplasmic component of NFAT was independently discovered by two groups and called NFATc [83] and NFATp [85] . Recently, the characterization of the genes that encode this component has revealed that NFAT is not a single protein but actually comprises a family of related factors. To date, four members of this family have been identified (Table 2) , which are differentially distributed in lymphoid and non-lymphoid tissues and exhibit distinct binding preferences for recognition sites in cytokine genes [86, 87] . These NFAT proteins sharẽ 70% sequence identity within a C-terminal DNAbinding region distantly related to the Rel homology domain of the NF-κB transcription factors [86, 88] . They also have significant homology in their N-terminal [107] . The rapid nuclear export of NFAT upon rephosphorylation may provide one mechanism for cells to discriminate among calcium signaling patterns and explains why elevation of [Ca 2+] i must be maintained above a certain threshold [111] for several hours to commit T cells to maximally express the IL-2 gene [112] . Most interestingly, while the inhibition of CaN by FK506 prevents NFAT dephosphorylation, and thereby its nuclear import, this inhibition is also effective after NFAT has migrated to the nucleus, to cause the return of NFAT to the cytoplasm and the termination of ongoing IL-2 gene transcription [100, 105] . Such a reversal of NFAT nuclear localization (and transcriptional activity) by FK506 is consistent with earlier studies showing that the drug still suppresses T cell activation when added after the initiation of Ca 2+ signaling, albeit within a narrow time-window (30-60 min) [57] .
Inhibition of Oct-1 Activity
Oct-1 has been shown to represent another target for FK506-mediated inhibition of IL-2 transcription [82] . The drug strongly inhibits Oct-1-dependent transcription, but does not affect Oct-1 expression or DNA binding activity in T cells [81] . This apparent paradox led to the discovery of the octamer-associated protein, OAP, a 40 kDa inducible protein containing jun family members, which cooperates with Oct-1 to mediate transcriptional activation. FK506 does not suppress the induction of OAP by PMA and Ca 2+ , but rather alters its activity [113] . Another Oct-1 coactivator (perhaps related to OAP), termed BOB.1 (OBF.1) was recently identified [114] . The expression of this protein (~ 35 kDa), rapidly induced in T cells upon activation, is blocked by FK506. Furthermore, BOB.1 needs to be phosphorylated by an unidentified kinase to exert its transactivating function, and FK506 also inhibits this postranslational modification [114] . Hence, FK506 appears to interfere with the coactivation of Oct-1 at several levels in T cells (Fig. 2 ) . Note however, that the role of BOB-1 in the regulation of IL-2 transcription is as yet unclear since T cells from BOB-1 knock out mice can still express IL-2 upon activation with ionomycin + PMA [115] .
A crucial role for the abrogation of NFAT nuclear translocation by FK506 in its suppression of IL-2 production was demonstrated by the observation that Jurkat cells in which both NFATc1 and NFATc2 were expressed constitutively in the nucleus, in a manner independent of calcium signaling, became resistant to FK506 in terms of IL-2 gene activation [105] . Yet, the targeted disruption of individual NFAT genes in mice (Table 2) did not result in the profound immunodeficiency that one would have expected if the inhibition of NFAT activity was solely responsible for the immunosuppressive action of FK506. These surprising observations may indicate some level of functional redundancy within NFAT family members, and that all NFAT proteins may need to be inactivated at once, as achieved by CaN blockade, in order to cause immunosuppression. However, the gene knock-out studies clearly revealed that each NFAT family members may actually perform distinct functions in regulating immune responses, and that a subtle balance between these members may govern cytokine gene expression and the development of T cell functions. In fact, while NFATc1 ablation impaired Th2 responses [93, 94] , such responses were enhanced in NFATc2 knock-out mice [95, 96] , suggesting that these two NFAT proteins may regulate Th1/Th2 cell development antagonistically. It is also intriguing that NFATc1 knock-out mice suffered from a defect in cardiac valve formation [91, 92] , and one cannot help but wonder whether this defect might be mechanistically related to the cardiomyopathy found in FKBP12 knock-out mice [37] . In any case, the important lesson from these genetic experiments, as far as the mechanism of immunosuppressive action of FK506 is concerned, has been to substantiate the notion that even though NFAT inhibition plays a major part in this mechanism, it is not sufficient to explain all of it.
Inhibition of NF-κB Activity
The modulation of NF-kB activity by FK506 may also contribute to the drug's immunosuppressive effect [82, 116] . The NF-κB transcription factor is a heterodimer composed of p50 and p65 subunits related to the Rel family of DNA-binding proteins, which is constitutively expressed in most cell types in a latent form [117] . This heterodimer normally resides in the cytoplasm of uninduced cells complexed with a cytoplasmic retention protein, the inhibitor of NF-κB, IκB. When cells are stimulated, IκB is phosphorylated and degraded, releasing NF-κB which is then free to enter the nucleus and activate transcription [117] . Stimulation of Jurkat cells with ionomycin plus PMA leads to the emergence of a phosphorylated form of IκB [118] . The Ca 2+ -dependent arm of this induction is blocked by FK506, thereby reducing NF-κB nuclear translocation and transcriptional activity [81, 116, 118] (Fig. 2 ) . Unlike the modulation of NFAT, it appears that in this case, CaN acts indirectly, perhaps by enhancing the activity of an IκB protein kinase acting in concert with PKC [118] or Raf-1 [119] .
Modulation of AP-1 and C-FOS Expression by FK506
FK506 exerts little or no inhibitory effect on the transcriptional activity mediated by AP-1 [82] . When driven by a combination of ionomycin + PMA in Jurkat cells, this activity was found to be, instead, augmented by the drug [113, 118] . In this situation, FK506 appeared to block a down-regulating effect of Ca 2+ -signaling events evoked by ionomycin on PMAmediated AP-1 induction [118] . Interestingly, the induction of AP-1 DNA-binding activity by ionomycin alone in a murine T cell lymphoma was also found to be markedly potentiated by either CsA [120] or FK506 [121] . This was shown to reflect predominantly an upregulated expression of c-fos [120, 121] , a component of AP-1 [122] . Moreover, the FK506 analog antagonist, L-685,818 failed to augment AP-1 DNA-binding activity and c-fos expression but blocked the enhancing effect of FK506 in this system (Fig. 3A ) . Therefore, CaN exerts a negative influence, which is reversed by FK506, on c-fos/AP-1 induction elicited by Ca 2+ signaling. This implies that Ca 2+ signaling has also a positive role in inducing AP-1, which is resistant to FK506. Such a role may be mediated by Cam kinase IV, as this enzyme was shown to activate, in a Ca 2+ -dependent manner, reporter gene constructs driven by AP-1 in T cells [123] , as well as c-fos expression in T cells [123] and brain cells [124] .
was obtained that CaN acts as the predominant phosphatase that dephosphorylates the transcription factor Elk-1, and thereby inhibits its activity which is known to be involved in c-fos induction [125,126a,b] . Consistently, CsA increased Elk-1 phosphorylation induced by EGF, while treatment with ionomycin inhibited this phosphorylation in COS cells [126a] . This is an important finding, which may explain some of the effects of FK506, not only on c-fos induction (Fig. 3B ) , but also on cytokine regulation and perhaps other events mediating the drug's toxicity.
Differential Modulation of Lymphokine Production by FK506
Although the suppression of IL-2 secretion is implicated in the blockade of T cell proliferation by FK506 or CsA in vitro [6] , IL-2 does not reverse CsA immunosuppression in vivo [127] . This demonstrates that the immuno-suppressive effect of these drugs results from multiple alterations of the immune response, besides IL-2 inhibition. Indeed, it is clear that FK506 affects the regulation of many genes of T cell activation [8] . Although the molecular mechanisms through which FK506 inhibits IL-2 gene transcription might serve as a paradigm for its action on such other T Recent studies suggest a potential mechanism for the negative role of CaN on c-fos induction. Evidence cell activation genes, the organization of the promoter/enhancer region of these genes still remains to be fully characterized. However, DNA sequences that may bind different NFAT family members, have been noted for many lymphokine genes [86] . Most likely, such NFAT proteins provide targets for inhibition by FK506 when these genes are induced via calciumdependent signaling [86] . Recently, it has been shown that in the case of IFN-γ , the promoter regions that are most critical for the gene's regulation also contain NFAT-binding sites [128] . Furthermore, the ligands for CD40 [129] and for CD95 [130] , whose expression on the cell surface after T cell activation is blocked by FK506, have been shown to be regulated via NFATbinding sites. Moreover, a sequence binding NAFTc1 is present in the HIV-1 promoter and regulates HIV-1 replication and gene expression in T cells, which may explain its sensitivity to CsA and FK506 [131] . NFAT has also been recently implicated in the induction of EBV lytic switch by Ca 2+ signaling in B cells, an event which is inhibited by FK506 [132] .
speculate that in this instance, the paradoxical effect of the drug may have been related to an enhanced IL-13 production since this cytokine shares with IL-4 the ability to promote IgE synthesis [136] .
It is also noteworthy that the production of two chemokines, MIP-1α and MIP-1β is strongly inhibited by FK506 [137] . This is likely to play a significant role in the drug's immunosuppressive effect, since these chemotactic factors are involved in recruiting T cells and monocytes at the site of immune responses.
Disruption of Intrathymic T Cell Development by FK506
Besides altering cytokine production, FK506 also disturbs T cell development, an effect which may contribute to its immunosuppressive activity. In rats or mice, FK506 has been shown to cause a dramatic elimination of phenotypically mature T cells in the thymus, reflected histologically by a selective atrophy of the thymic medulla [138] [139] [140] . The post-CD4 + 8 + maturation of both CD4 + 8 -and CD4 -8 + subsets was found to be disrupted to a similar extent, while CD8 + TCR/CD3 low cells, the immediate precursors for CD4 + 8 + thymocytes, were spared by such a treatment [141] . A 4-day regimen of daily intravenous injections of the drug was sufficient to cause a nearly maximal depletion of mature thymocytes, which lasted for at least 3 days after cessation of the treatment [141] . Interestingly, this effect on thymopoiesis was shown to correlate with an inhibition of CaN activity in the thymus [142] and with the ability of FK506 analogs to inhibit CaN in vitro [141] . Recent studies suggested that the cRel protein whose induction is inhibited by FK506, may be a common CaN-dependent effector of CD4 + 8 + to CD4 + 8 -and CD4 -8 + transition [143] , and this may represent a target for the drug's effect on positive selection. In addition, NFATc3 whose expression is highest in CD4 + 8 + cells [144] is certainly involved in this process since NFATc3 knock-out mice exhibit a marked defect in intrathymic positive selection [98] .
It is important to consider that the regulation of T cell activation genes by FK506 depends greatly on the mode of activation through which they are induced. For instance, it has been kown for some time that the induction of IL-2 production upon activation of T cells with anti-CD28 mAb + PMA, is resistant to inhibition by CsA or FK506 [7] . This mode of activation does not involve calcium signaling, although it may still recruit NFAT, independently of CaN [133] .
Recently, we have conducted a comparative analysis of the effect of FK506 on cytokine production by human T cells activated by anti-CD3 mAb in combination with either PMA or anti-CD28 mAb [134] . As expected [8] , induction of these cytokines via CD3/PMA was sensitive to FK506 inhibition. However, the production of IL-5, IL-13, IFN-γ and GM-CSF was enhanced by FK506 when induced via CD3/CD28 stimulation. Therefore, FK506-sensitive events, acting transcriptionally or post-transcriptionally contribute differently to the regulation of these T-cell derived cytokines. In the CD3/CD28 mode of activation, the FK506-sensitive CaN-dependent signaling mediated via CD3, may down-regulate IL-5, IL-13, IFN-γ and GM-CSF induction, perhaps through an effect on Elk-1/cfos [126] . Moreover, at least in the case of IL-5 and IL-13, it is conceivable that the enhancement by FK506 might reflect an inhibition of NFATc2 activity, since NFATc2 knock-out mice show an increased production of these two cytokines [97] . The possible clinical implications of this differential regulation of cytokine production by FK506 observed in vitro is unclear. However, it is interesting that, in an infant with autoimmune entheropathy, FK506 therapy was found to cause an elevation of IgE, even though IL-4 production was suppressed [135] . One might
The role of CaN in the negative selection process mediated by apoptosis at the CD4 + 8 + stage [145] is less clear. FK506 is able to block activation-driven apoptosis in T cell hybridomas [144, 146] , through an inhibition of CD95 ligand expression [147, 148] . However, FK506 treatment did not increase the absolute number of CD4 + 8 + thymocytes which would be expected if the apoptotic mechanism of negative selection was blocked. Instead, this number was reduced by over 50 % [141] . Hence, along with the observations that FK506 augments anti-CD3 antibodyinduced CD4 + 8 + thymocyte death in vivo [149] and in vitro upon co-stimulation through CD4, CD8 or LFA-1 [150] , it is possible that CaN is involved in delivering an anti-apoptotic signal that counteracts intrathymic negative selection. Further along these lines, it was recently shown that FK506 cancels the mutual inhibition of activation-and dexamethasone-induced DNA fragmentation in T cell hybridomas [151] and potentiates corticosteroid-induced apoptosis of thymocytes in vivo [152] .
the drug with the activity of any of the above mentioned transcription factors contributes to this inhibition. Interestingly, preliminary evidence for a calciumdependent elevation of AP-1 DNA-binding activity in the kidney of CsA-treated rats has been obtained [168] . If it also occurs with FK506, such an alteration might be linked to the role of CaN in regulating Elk-1 phosphorylation [126] (Fig. 3B ). An effect of FK506 on gene regulation might also underlie the increased TGF-β production associated with the fibrosis of chronic FK506 nephropathy [161] . Furthermore, it has recently been proposed that FK506-induced nephropathy might be related to an overproduction of IL-6 via an upregulation of NF-κB activity [169] . However, this observation could not be reproduced in our laboratory.
Mechanisms of FK506 Toxicity
The greatest limitation to the therapeutic potential of FK506 comes from its toxic side effects, that include neurotoxicity, nephrotoxicity, diabetogenicity, and gastrointestinal disturbances [9, 10, 14, 15] (Table 3 ). The precise pathophysiological mechanisms of FK506 toxicity are still enigmatic, in part because the cells that are actually implicated within the target tissues of this toxicity have not been clearly identified. However, evidence has accumulated that the side effects of FK506 arise from the same biochemical mechanisms that underlie its immunosuppressive effects, namely an inhibition of CaN activity in various tissues. This is suggested by the fact that the toxicity profile of FK506 overlaps with that of CsA [14] and is totally different from that of rapamycin [3, 153, 154] . Furthermore, FKBP12-binding analogs of FK506 that do not inhibit CaN function are devoid of toxicity [27, 28, 154] and the antagonist of FK506-induced immunosuppression, L-685,818, can block FK506-induced toxicity in animal models [27, 155, 156] .
It is also likely that FK506 toxicity reflects alterations of CaN substrates not directly involved in gene regulation [157] . For instance, the activity of the membrane Na + /K + ATPase pump has been shown to be CaN-dependent and to be inhibited by FK506 in kidney tubules, and this may participate in nephrotoxicity and hyperkalemia [160] . An action of FK506 on certain secretory mechanisms involving calcium-induced exocytosis [170] may also contribute to toxicity. Furthermore, FK506 has been shown to inhibit endocytosis of neuromediators and synaptic vesicle recycling at nerves terminals, through an indirect action on the GTPase dynamin I, a CaN substrate [171, 172] . FK506 also potentiates postsynaptic transmission in hippocampal neurons [173] . Moreover, an increase in smooth muscle contractibility which may contribute to the gastrointestinal alterations induced by FK506, such as intuscusseption, may be related to the stimulation by the drug of tachykinin activation of L-type Ca 2+ channels [164] . Also, CaN inhibition might mediate hypertension through sympathetic neural activation, perhaps contributing to FK506 nephrotoxicity [159] . In addition, evidence was obtained that FK506 can affect cAMP-dependent physiological responses by influencing cAMP formation [174, 175] .
FK506 might affect its cellular targets of toxicity at the gene transcription level, through an action on CaNregulated ubiquitous transcription factors, such as NFkB [118] or Elk-1 [126] . Some members of the NFAT family (Table 2 ) may also be involved [165, 166] , as well illustrated by the embryonic toxicity found in NFATc1-deleted mice [91, 92] . Moreover, the activity of the widely distributed cAMP-responsive transcription factor, CREB, has been shown to be modulated in a CaN-dependent fashion by FK506 [167] . One of the toxic effects of FK506 mediated at the level of gene regulation may be diabetogenicity, possibly caused by an inhibition of insulin gene transcription [162, 163] . However, it as yet unclear whether an interference of If the inhibition of CaN activity is involved in mediating the side effects of FK506, one may wonder why the drug is not more toxic, given the widespread Table 3 .
Major side effects of FK506 and their possible mechanisms
Toxicity Putative mechanisms
Neurotoxicity Alterations of synaptic transmission [157] , inhibition of NO synthase [158] Nephrotoxicity Sympathomimetic activation [159] , inhibition of Na + /K + ATPase [160] , increased TGF-β production [156] Diabetes Inhibition of insulin gene transcription [162, 163] GI toxicity Sympathomimetic activation [159] ,smooth muscle activation [164] distribution of this enzyme [176] . There are however large variations in abundance and isoform distribution pattern of CaN in different tissues [177] [178] [179] . This, together with tissue-dependent variations in FKBP content could explain the relative selectivity of action of FK506. It seems likely that the drug will preferentially affect those cells in which FKBP12 exists in vast excess of CaN, as is the case for T cells [178] . The subcellular localization of FKBP12, and of CaN and its subtrates [180] , might also determine the drug sensitivity of a given CaN-dependent cellular event.
The differential partition of FK506 within different tissues, is another parameter that may influence the organ selectivity of its action. Due to its lipophilicity, FK506 rapidly enters cells by passive diffusion [56] . However, this lipophilicity also results in a high affinity of FK506 for the multidrug resistance (MDR) pathway, an active extrusion process mediated by the Pglycoprotein family [181] . Although at high concentrations, FK506 inhibits MDR function [182, 183] , at low concentrations it is pumped out of cells expressing high P-glycoprotein levels [184a,b] . This might significantly affect the biodistribution of FK506, and for instance, impede its penetration through MDR positive endothelial cells of the bloodbrain-barrier [185] , which would mitigate the drug's CNS toxicity.
legal reasons, most of this chemistry has centered around the naturally occuring and patent-free C21-ethyl analog of FK506, ascomycin (L-683,590, Fig. 1 ), which was described over 25 years ago as an antifungal antibiotic [189] , and whose immunosuppressive properties were recognized in our laboratory [27] . In this search for analogs with diminished toxicity but preserved immunosuppressive activity, over thousand compounds were generated [188, [190] [191] [192] , providing the basis for detailed SAR analyses. This effort also led to the discovery of antagonistic compounds, such as L-685,818 [27] . (Fig. 1 ) and the natural product, meridamycin [193] . In addition, compounds with mixed agonist/antagonist immunosuppressive activity were identified, as exemplified by the C32-Omethoxyethoxymethyl ascomycin derivative (L-688,617, Fig. 1 ). The latter activity was shown to reflect a high affinity of the compound for FKBP12 combined with a reduced ability of the immunophilin-drug complex to inhibit CaN function [194] .
The evaluation of the biological activity of the FK506 analogs produced in our program demonstrated that, in general, the toxicity of these analogs is quantitatively correlated with their immunosuppressive potency and ability to interact with both FKBP12 and CaN (Dumont et al., unpublished observations). However, we recently identified a chemical modification of the macrolide structure which results in unique pharmacological properties such that the toxic and immunosuppressive activities of the compound are partially uncoupled. This compound, designated L-732,531, is the C32-O-indolyl derivative of ascomycin (Fig. 1 ) . L-732,531 was found to exhibit a potency 2-fold greater than ascomycin and nearly equivalent to that of FK506 in inhibiting CaN phosphatase activity, IL-2 promoter activity and T cell activation in vitro [195, 196] . The immunosuppressive activity of L-732,531 was further documented in vivo where it also proved to be equipotent with FK506 in prolonging mouse skin and thyroid allograft survival [195] . In contrast L-732,531 was found to be 3-fold less potent than FK506 in inducing hypothermia, an indicator of neurotoxicity, and in causing gastrointestinal toxicity, in mice. Furthermore, L-732,531 was at least 2-fold less nephrotoxic than FK506 upon 3-week oral treatment in rats maintained on normal or sodium-depleted diet [195] .
Noteworthily, some of the non-immunological effects of FK506 are not all deleterious but may in fact lead to novel therapeutic applications of the drug or its derivatives. This is certainly the case for the recently discovered action of FK506 on nerve regeneration [186,187a] . Systemic administration of FK506 in rats was shown to accelerate the regrowth and functional recovery of crushed sciatic nerves [186] . Most interestingly, L-685,818 proved to be as effective as FK506 in such a system [187a] , suggesting that this neurotrophic effect is not mediated by an inhibition of CaN. Indeed, novel non-immunosuppressive FKBP ligands have been synthetized, which also augment the recovery of damaged sciatic nerves [186] and of chemically-lesioned brain neurones as well [187a] . Interestingly, this neurotrophic action of FKBP ligands may involves FKBP52 and not FKBP12 [187b] . Its potential utility for the treatment of neurodegenerative disorders, spinal cord injury and stroke warrants further investigation.
The Search for Less Toxic FK506 Analogs
Most interestingly, this unexpected biological activity profile of an FK506-related compound, revealing a dissociation between immunosuppression and toxicity, was found to be accompanied by unusual biochemical properties. Evidence was obtained that L-732,531 binds approximately 10-fold less than FK506 or ascomycin to FKBPs in T cells [195] and to purified FKBP12 in vitro [196] , making the increase in immunosuppressive potency of L-732,531 compared Large chemistry efforts were launched early on after the discovery of FK506 with the hope of improving upon its therapeutic index [188] , even though immunosuppression and toxicity of this class of compound appeared to be mechanistically linked. For to ascomycin all the more intriguing. An explanation for this apparent discrepancy was provided by the finding that the poor affinity of L-732,531 for FKBP12 is compensated for by an enhanced affinity of the FKBP12/drug complex for CaN [196] . It was shown that once the ternary complex between CaN and the FKBP12/drug complex has formed, the off-rate of the drug from this complex is about 15-fold less for L-732,531 than for FK506. This enhanced stability of the interaction between the FKBP12/L-732,531 complex and CaN may indicate that the indole moiety of the drug, projecting out of the effector face of the complex, provides an additional contact point with CaN [196] . Indeed, insertion of this indole group at the C32 position in L-685,818 was found to increase the affinity for CaN of the compound bound to FKBP12 by 100-fold and to convert L-658,818 from an antagonist to an agonist [190] . This is in marked contrast to the Omethoxyethoxymethyl group which, when introduced at the same position, appears to act as a repellent for interaction of the FKBP12/drug complex with CaN [194] . utility than FK506 for the management of autoimmune and inflammatory diseases. Studies towards this goal have been continuing in our laboratories [197] [198] [199] .
Note Added in Proof
Since completion of this review, a number of novel observations relevant to the mode of action of FK506 have been published. In particular, it was reported that FK506 inhibits hypertrophic myocarditis in murine models, through CaN-mediated inhibition of NFATc4 activity [200] [201] [202] . CaN was also found to regulate the differentiation and growth of skeletal muscle fibers [203] [204] [205] . These findings further demonstrate the role of CaN in non-lymphoid cells and may have implications for the mechanism of toxicity of FK506. Moreover, CaN was shown to dephosphorylate and inactivate Cam kinase IV [206] , which adds complexity to the Ca 2+ signaling mechanisms outlined in Fig. 3B . Furthermore, a large molecular weight protein inhibitor of CaN expressed in a variety of tissues, including T cells, was identified [207, 208] . Along with the anchorage protein, AKAP79 [209] , this new protein is likely to contribute to the regulation of CaN activity. A smaller protein produced by the African swine fever virus was also shown to inactivate CaN and to block NFAT-mediated transcription in host lymphoid cells, thereby preventing cytokine production [210] . It is humbling that this virus evolved to target the signaling ability of CaN for eluding immune recognition, turning to its advantage the same molecular mechanisms exploited by mankind's most advanced immunosuppressants.
It seems plausible that the anomalous biochemical properties of L-732,531 contribute to its differential activity on target cells for immunosuppression and toxicity. CaN inhibition by L-732,531 may be favored in cells that contain high excess of FKBP12 vs CaN, such as T cells [178] whereas cells with low FKBP12 to CaN ratios would be more resistant to CaN inhibition by L-732,531 than by FK506. It is also possible that the two compounds affect differently CaN isoforms that may have distinct physiological roles [179] . A differential tissue distribution of L-732,531 might also account for its reduced toxicity compared to FK506. Perhaps, due to its decreased binding to intracellular FKBPs, L-732,531 may be exported out of cells by the MDR pathway more efficiently than FK506, and this could be important regarding the induction of neurotoxicity. Such hypotheses are currently being explored.
Interestingly, another ascomycin derivative was recently described which in terms of nephrotoxicity, displays an even better therapeutic window vs FK506 than L-732,531 [155] . This compound, A-119435, has a hydroxyethylether substitution at the C32 position (Fig. 1 ) . A comparison of its biochemical properties with those of L-732,531 would certainly be very instructive. However, at the moment there is no information available concerning these properties in the case A-119435. Further work is therefore needed to better define the biological and molecular parameters that account for the amelioration of pharmacologic activity profile of A-119435 and of L-732,531 as well. One may anticipate that such studies will provide new insights into the mechanisms of FK506 toxicity and, perhaps, help design a next generation of compounds with greater improvement in therapeutic index and wider
